Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.
Want the full AI research report for FOSUN PHARMA?
This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.
New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.
10-Year FinancialsFY2016–2025
Financial statements are reported in CNY, while share price and market cap are quoted in HKD.
Key Multi-Year Facts
- Revenue moved from CN¥14.51B in FY2016 to CN¥41.50B in FY2025 (9-year CAGR +12.4%).
- Profitable in every fiscal year across 2016–2025.
Latest 5 Fiscal Years
| Fiscal Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue (CNY B) | 38.9 | 43.8 | 41.2 | 40.9 | 41.5 |
| YoY | 28.8% | 12.7% | -5.8% | -0.8% | 1.4% |
| Net Income (CNY B) | 4.73 | 3.74 | 2.40 | 2.77 | 3.37 |
| YoY | 29.1% | -21.0% | -35.8% | 15.5% | 21.7% |
| Operating Cash Flow (CNY B) | 3.94 | 4.22 | 3.41 | 4.48 | 5.21 |
| ROE | 12.4% | 8.9% | 5.3% | 6.0% | 7.0% |
| Gross Margin | 47.9% | 47.1% | 47.6% | 47.8% | 49.9% |
| Net Margin | 12.2% | 8.5% | 5.8% | 6.8% | 8.1% |
| Debt-to-Assets | 48.2% | 49.5% | 50.1% | 49.0% | 48.5% |
Show all 10 fiscal years
| Fiscal Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (CNY B) | 14.5 | 18.4 | 24.7 | 28.4 | 30.2 | 38.9 | 43.8 | 41.2 | 40.9 | 41.5 |
| YoY | — | 26.6% | 34.6% | 14.9% | 6.2% | 28.8% | 12.7% | -5.8% | -0.8% | 1.4% |
| Net Income (CNY B) | 2.81 | 3.12 | 2.71 | 3.32 | 3.66 | 4.73 | 3.74 | 2.40 | 2.77 | 3.37 |
| YoY | — | 11.4% | -13.3% | 22.7% | 10.3% | 29.1% | -21.0% | -35.8% | 15.5% | 21.7% |
| Operating Cash Flow (CNY B) | 2.11 | 2.58 | 2.95 | 3.22 | 2.58 | 3.94 | 4.22 | 3.41 | 4.48 | 5.21 |
| ROE | 12.7% | 13.2% | 10.2% | 11.1% | 10.7% | 12.4% | 8.9% | 5.3% | 6.0% | 7.0% |
| Gross Margin | 53.7% | 58.6% | 58.1% | 59.3% | 54.5% | 47.9% | 47.1% | 47.6% | 47.8% | 49.9% |
| Net Margin | 19.3% | 17.0% | 11.0% | 11.7% | 12.1% | 12.2% | 8.5% | 5.8% | 6.8% | 8.1% |
| Debt-to-Assets | 42.4% | 52.1% | 52.4% | 48.5% | 45.1% | 48.2% | 49.5% | 50.1% | 49.0% | 48.5% |
Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings
Risk ChecklistAs of 2026-11-05
Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).
Items Flagged for Review
- Watch
-
Watch
Short-Term Debt CoverageSolvency
Cash CN¥13.30B, short-term debt CN¥15.49B (0.86x)
Q3 (2026-09-30) · What is this?
An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.
Dividends
Trailing 12-month dividend: HK$0.450 per share, or 2.65% yield at closing price; last full fiscal year: HK$0.450 (payout ratio 29.7%).
Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.
More data: All research reports · Sector leaders · Market hours & holidays.
Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.